Xortx reprices warrants issued in connection with previous private placements

Calgary, alberta, april 30, 2024 (globe newswire) -- xortx therapeutics inc. (“xortx” or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of march 11, 2024, the company has received tsx venture exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common share purchase warrants (“warrants”) by amending the exercise price to usd $5.00 per share as follows:
XRTX Ratings Summary
XRTX Quant Ranking